As of Thursday close, BridgeBio Pharma Inc.’s (NASDAQ:BBIO) stock was up $0.1, moving up 0.31 percent to $32.10. The average number of shares traded per day over the past five days has been 2,525,900 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.03 fall in that time frame. In the last twenty days, the average volume was 5,756,385, while in the previous 50 days, it was 3,456,258.
Since last month, BBIO stock rose 83.53%. Shares of the company fell to $16.61 on 07/05/23, the lowest level in the past month. A 52-week high of $36.36 was reached on 07/18/23 after having rallying from a 52-week low of $6.55. Since the beginning of this year, BBIO’s stock price has risen by 321.26% or $24.48, and marked a new high 21 times. However, the stock has declined by -11.72% since its 52-week high.
BBIO stock investors should be aware that BridgeBio Pharma Inc. (BBIO) stock had its last reported insider trading activity 17 days ago on Jul 18. VIKING GLOBAL INVESTORS LP, the 10% Owner of the company, disposed of 1,500,000 shares for $35.00 on Jul 18. It resulted in a $52,500,000 divestment by the insider. Kumar Neil sold 51,552 shares at an average price of $14.01 on May 17. The insider now owns 4,813,197 shares following the transaction. On May 17, Secretary, Treasurer & CFO STEPHENSON BRIAN C sold 24,424 shares at $14.01 apiece. The transaction was valued at $342,168.
Financial Health
In the three months ended March 30, BridgeBio Pharma Inc.’s quick ratio stood at 5.70, while its current ratio was 5.70, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 96.50% percent. Based on annual data, BBIO earned $74.21 million in gross profit and brought in $77.65 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -113.10%. Return on equity (ROE) for the past 12 months was 36.60%.
In BridgeBio Pharma Inc.’s quarter-end financial report for March 30, it reported total debt of $435.76 million against cash and short-term investments of $34.12 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. BBIO’s revenue rose 7.65% to $1.87 million during the quarter, while net income inched up to $1.83 million. While analysts expected BridgeBio Pharma Inc. to report -$0.83 quarterly earnings, the actual figure was -$0.92 per share, beating the consensus estimate by -10.80%. During the quarter, the company generated -$124.53 million in EBITDA. The liabilities of BridgeBio Pharma Inc. were 1.84 billion at the end of its most recent quarter ended March 30, and its total debt was $1.73 billion. The value of shareholders’ equity is $160.5 million.
Technical Picture
This quick technical analysis looks at BridgeBio Pharma Inc.’s (BBIO) price momentum. With a historical volatility rate of 55.18%, the RSI 9-day stood at 61.01% on 03 August.
With respect to its five-day moving average, the current BridgeBio Pharma Inc. price is down by -0.09% percent or -$0.03. At present, BBIO shares trade +88.82% above its 20-day simple moving average and +128.31% percent above its 100-day simple moving average. However, the stock is currently trading approximately +134.14% above its SMA50 and +224.90% above its SMA200.
Stochastic coefficient K was 74.91% and Stochastic coefficient D was 84.15%, while ATR was 2.12. Given the Stochastic reading of 57.70% for the 14-day period, the RSI (14) reading has been calculated as 66.58%. As of today, the MACD Oscillator reading stands at -0.34, while the 14-day reading stands at -0.48.
Analyst Ratings
BridgeBio Pharma Inc. downgraded its rating on BridgeBio Pharma Inc. (NASDAQ: BBIO) to a Hold in a note to investors on July 18, 2023. The analysts firm previously had a Buy rating on the stock.BridgeBio Pharma Inc. (BBIO) has been rated Buy by analysts. According to 0 brokerage firms, BBIO is a sell, and 1 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate BridgeBio Pharma Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $47.00, the current consensus forecast for the stock is $33.00 – $51.00. Based on these forecasts, analysts predict BridgeBio Pharma Inc. (BBIO) will achieve an average price target of $45.20.
